156 related articles for article (PubMed ID: 38540125)
21. Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia.
Shimony S; Liu Y; Valtis YK; Paolino JD; Place AE; Brunner AM; Weeks LD; Silverman LB; Vrooman LM; Neuberg DS; Stone RM; DeAngelo DJ; Luskin MR
Blood Adv; 2023 Apr; 7(7):1092-1102. PubMed ID: 36508268
[TBL] [Abstract][Full Text] [Related]
22. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.
Gökbuget N; Basara N; Baurmann H; Beck J; Brüggemann M; Diedrich H; Güldenzoph B; Hartung G; Horst HA; Hüttmann A; Kobbe G; Naumann R; Ratei R; Reichle A; Serve H; Stelljes M; Viardot A; Wattad M; Hoelzer D
Blood; 2011 Sep; 118(13):3504-11. PubMed ID: 21715318
[TBL] [Abstract][Full Text] [Related]
23. The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma.
Dabaja BS; Ha CS; Thomas DA; Wilder RB; Gopal R; Cortes J; Bueso-Ramos C; Hess MA; Cox JD; Kantarjian HM
Cancer; 2002 May; 94(10):2738-44. PubMed ID: 12173345
[TBL] [Abstract][Full Text] [Related]
24. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions.
Miller LH; Maxa KL; Winter SS; Gossai NP
Expert Rev Anticancer Ther; 2023; 23(12):1229-1236. PubMed ID: 37850259
[TBL] [Abstract][Full Text] [Related]
25. Management of Nelarabine induced neurotoxicity in a child with T-cell acute lymphoblastic lymphoma.
Karthik U; Motwani J
J Oncol Pharm Pract; 2024 Apr; 30(3):594-596. PubMed ID: 38105625
[TBL] [Abstract][Full Text] [Related]
26. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Frey NV; Luger SM
Blood; 2015 Jul; 126(5):589-96. PubMed ID: 25966988
[TBL] [Abstract][Full Text] [Related]
27. Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine.
Morita K; Jain N; Kantarjian H; Takahashi K; Fang H; Konopleva M; El Hussein S; Wang F; Short NJ; Maiti A; Sasaki K; Garcia-Manero G; Konoplev S; Ravandi F; Khoury JD; Jabbour E
Am J Hematol; 2021 May; 96(5):589-598. PubMed ID: 33639000
[TBL] [Abstract][Full Text] [Related]
28. Bilateral nephromegaly due to direct leukemic cell invasion in the initial and relapse phases of T-cell acute lymphoblastic leukaemia: A case report.
Tamura Y; Sumiyoshi R; Yamamoto T; Hayama Y; Fujigaki Y; Shibata S; Sasajima Y; Tashiro H
Medicine (Baltimore); 2021 Dec; 100(51):e28391. PubMed ID: 34941173
[TBL] [Abstract][Full Text] [Related]
29. Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript.
Voruz S; Blum S; de Leval L; Schoumans J; Solly F; Spertini O
Biomark Res; 2021 Dec; 9(1):92. PubMed ID: 34930453
[TBL] [Abstract][Full Text] [Related]
30. Precursor T-Cell acute lymphoblastic leukemia/lymphoma with rare presentation in the urinary bladder.
Pham A; Steinberg A; Kwok B; Lopez A; Lim S; Lill M
Hematol Rep; 2011 Aug; 3(2):e18. PubMed ID: 22184539
[TBL] [Abstract][Full Text] [Related]
31. Nelarabine-induced rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia: a case report.
Utsumi A; Goto Y; Suzuki T; Imai C; Matsui S; Sakaida E; Ishii I
J Pharm Health Care Sci; 2022 Jun; 8(1):17. PubMed ID: 35690835
[TBL] [Abstract][Full Text] [Related]
32. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults.
Si Lim SJ; Ford JB; Hermiston ML
Blood; 2023 Jun; 141(25):3019-3030. PubMed ID: 37018730
[TBL] [Abstract][Full Text] [Related]
33. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma.
Cohen MH; Johnson JR; Massie T; Sridhara R; McGuinn WD; Abraham S; Booth BP; Goheer MA; Morse D; Chen XH; Chidambaram N; Kenna L; Gobburu JV; Justice R; Pazdur R
Clin Cancer Res; 2006 Sep; 12(18):5329-35. PubMed ID: 17000665
[TBL] [Abstract][Full Text] [Related]
34. Study of Three Cases of Primary Refractory T Cell ALL.
Singh R; Tejwani N; Agrawal N; Kapoor J; Khushoo V; Mehta P; Ahmed R; Bhurani D
Indian J Hematol Blood Transfus; 2021 Jul; 37(3):497-499. PubMed ID: 34267473
[TBL] [Abstract][Full Text] [Related]
35. Nelarabine-associated myelopathy in a patient with acute lymphoblastic leukaemia: Case report.
Amer-Salas N; González-Morcillo G; Rodríguez-Camacho JM; Cladera-Serra A
J Oncol Pharm Pract; 2021 Jan; 27(1):244-249. PubMed ID: 32517638
[TBL] [Abstract][Full Text] [Related]
36. Lymphoblastic lymphoma.
Cortelazzo S; Ponzoni M; Ferreri AJ; Hoelzer D
Crit Rev Oncol Hematol; 2011 Sep; 79(3):330-43. PubMed ID: 21273093
[TBL] [Abstract][Full Text] [Related]
37. Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G
Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663
[TBL] [Abstract][Full Text] [Related]
39. Relapsed or Refractory Lymphoblastic Lymphoma in Children: Results and Analysis of 23 Patients in the EORTC 58951 and the LMT96 Protocols.
Michaux K; Bergeron C; Gandemer V; Mechinaud F; Uyttebroeck A; Bertrand Y;
Pediatr Blood Cancer; 2016 Jul; 63(7):1214-21. PubMed ID: 27037853
[TBL] [Abstract][Full Text] [Related]
40. Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia.
Shimony S; DeAngelo DJ; Luskin MR
Blood Adv; 2024 Jan; 8(1):23-36. PubMed ID: 37389830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
